PAI Pharma (PAI), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer, and marketer of oral liquid medicines and Ready-To-Use (RTU) sterile injectable and hospital-focused products, announced the acquisition of Nexus Pharmaceuticals, LLC (Nexus), a pharmaceutical company specializing in the development and commercialization of injectable medicines used in critical care, oncology, and other hospital settings.

The acquisition marks another significant step in PAI's strategy to build a broader portfolio of essential medicines and expand its presence in the hospital and sterile injectable markets. Nexus brings an established commercial portfolio of over 20 hospital injectable products, deep customer relationships, and extensive expertise in developing and commercializing critical therapies. Combined with PAI's leadership in Ready-to-Dose oral liquid medicines and growing sterile injectable business, including the recent acquisition of Nivagen and its aseptic manufacturing capabilities in Sacramento, the acquisition strengthens PAI's ability to serve hospitals and healthcare providers with a broader range of high-quality pharmaceutical products.

William Blair acted as exclusive advisor, and Kirkland & Ellis LLP acted as legal counsel to PAI Pharma, a portfolio company of Olympus Partners. Proskauer Rose LLP acted as legal counsel to Nexus Pharmaceuticals.